Replies to post #67337 on Biotech Values

[DewDiligence]

>PFE – what is the point of increasing earnings per share in the short run when their earnings are going to fall off of a cliff in 2011.<

You seem to be confusing the one-time drop in EPS from Lipitor’s patent expiration with the permanent boost to EPS that PFE could obtain from leveraging the balance sheet.